Group 1: Market Overview - The three major indices experienced fluctuations, with the Shanghai Composite Index up 0.01%, Shenzhen Component down 0.37%, and ChiNext down 0.01%. The STAR Market 50 Index rose by 0.45%. Over 1,200 stocks in the two markets saw gains, with a total trading volume of approximately 1.86 trillion yuan [2]. Group 2: Infrastructure Sector - Infrastructure stocks, particularly in the hydropower sector, performed strongly. Companies like China Railway Construction Heavy Industry (688425.SH) and Shenzhen Water Planning Institute (301038.SZ) surged by 20%, while others like China Power Construction (601669.SH) and Tibet Tianlu (600326.SH) hit the daily limit of 10% increase. This surge follows the announcement of a 1.2 trillion yuan hydropower project that commenced on July 19, which is expected to boost demand for construction materials such as cement and additives [2]. Group 3: Financial Sector - Financial stocks, including securities and insurance, showed significant activity. Guosen Securities (002736.SZ) and Guosheng Financial Holdings (002670.SZ) rose by about 5%, while Citic Securities (600030.SH) and New China Life Insurance (601336.SH) saw substantial gains. The A-share market is experiencing a resurgence, with financing balances exceeding 1.9 trillion yuan for the first time in three months, indicating a favorable environment for brokerage firms [3]. Group 4: Healthcare Sector - The CRO and medical stocks gained traction, with companies like Medisi (688202.SH) rising by 8.83%. Other firms such as Zhaoyan New Drug (603127.SH) and WuXi AppTec (603259.SH) also saw increases. According to China International Capital Corporation, the optimistic liquidity outlook for 2025 and breakthroughs in domestic AI technology suggest that innovative pharmaceutical assets are well-suited for the current investment climate [4]. Group 5: Steel Sector - Steel stocks performed well, with Xining Special Steel (600117.SH) and Jiugang Hongxing (600307.SH) increasing by 10%. The China Iron and Steel Association held a meeting on July 15, emphasizing the need to control capacity and prevent excess supply in the steel industry. Conversely, sectors such as military, lithium battery, and photovoltaic saw declines, with companies like Beifang Changkong (301357.SZ) dropping by 9.95% [5].

Core Viewpoint - Citi Group's Chief Economist for Greater China, Yu Xiangrong, emphasizes the importance of nominal growth recovery in the second half of the year, alongside maintaining real growth momentum, which will enhance the attractiveness of Chinese assets [3]. Economic Growth Forecast - Citi has raised its GDP growth forecast for China to 5% for the year, with actual growth in the first half reaching 5.3%, providing a solid foundation for achieving the annual target [2]. Export Performance - Exports are expected to slow down in the second half due to higher base effects but are likely to continue exceeding expectations, with a forecast of mid-single-digit positive growth for the year [6]. - In the first half of 2023, China's total export value reached 13 trillion yuan, a year-on-year increase of 7.2%, with machinery and electronics exports accounting for 60% of total exports [6]. Domestic Demand Recovery - Domestic demand is anticipated to show a differentiated recovery, with varying performance across industries, but overall growth is expected to remain on track [9]. - New economic sectors such as artificial intelligence, new consumption, and innovative pharmaceuticals are increasingly contributing to overall growth [10]. Consumer Behavior - Consumer confidence is gradually improving, with demand for travel, entertainment, and experience-based consumption rising, contributing to GDP growth [12]. - The sales of certain new energy vehicles, despite higher prices, indicate that consumer purchasing power remains robust for quality products [13]. Investment Trends - New capital expenditures and service sector investments are flourishing, with AI-related investments projected to contribute approximately 500 billion yuan to GDP growth [14]. Policy Outlook - Macro policies are expected to focus on coordinated supply and demand measures, with incremental policies likely to accelerate [15]. - Fiscal policies will emphasize new measures rather than budget modifications, including enhanced trade-in policies and timely childcare subsidies [16]. Real Estate Support - New supportive policies for the real estate sector are anticipated, including potential easing of restrictions in high-tier cities and adjustments to down payment ratios for second homes [17]. Supply-Side Reforms - The focus will be on substantial actions to address low-price competition and promote the orderly exit of outdated capacities [18]. - Specific measures may include tightening financial regulations and enhancing industry standards [19]. Conclusion - A new phase of supply-side reform is expected, which, if effectively implemented alongside demand-side stimulus, could lead to price recovery and bolster market confidence [20].

Group 1 - The core industries in the Sci-Tech Innovation Board are characterized by hard technology, with the electronic core industry (44.07%), biopharmaceutical industry (15.92%), and intelligent manufacturing equipment industry (9.15%) being the top three by market capitalization [1] - The demand for high-performance computing is resonating with the penetration of AI from the cloud to the edge, leading to an accelerated price increase in DDR4 and triggering a server upgrade cycle [1] - The innovative drug industry is expected to achieve breakthroughs through License-out overseas, with a projected transaction scale of $51.9 billion in 2024, indicating a continuous growth trend [1] Group 2 - Revenue growth rates for the electronic core industry, artificial intelligence industry, and biopharmaceutical industry in 2024 are projected to be 17.39%, 28.44%, and 32.36% respectively, with significant profit expectations for the biopharmaceutical industry [1] - The R&D intensity of the Sci-Tech Innovation Board remains stable at around 11%, with total R&D investment expected to reach 154.68 billion yuan in 2024, fostering a virtuous cycle of R&D-driven growth [1] Group 3 - The Sci-Tech Innovation Board 100 ETF (588120) tracks the Sci-Tech 100 Index (000698), which can have a daily price fluctuation of up to 20%. This index is compiled by China Securities Index Co., Ltd. and includes 100 securities with moderate market capitalization and good liquidity, reflecting the overall performance of outstanding growth enterprises in high-tech and strategic emerging industries [1] - The Sci-Tech Comprehensive Index ETF (589630) tracks the Sci-Tech Comprehensive Index (000680), also allowing for a daily price fluctuation of up to 20%. This index, published by the Shanghai Stock Exchange, selects all eligible listed companies on the Sci-Tech Innovation Board to reflect the overall market performance [2]

Core Insights - The Sci-Tech Innovation Board (STAR Market) has celebrated its sixth anniversary, having nurtured 589 listed companies with a total market capitalization exceeding 8.04 trillion yuan, focusing on "hard technology" sectors such as new-generation information technology and biomedicine [1] - The STAR 50 Index, which includes 50 high-growth, high-R&D technology leaders, has gained significant attention in the market, particularly in the context of active sectors like AI and innovative pharmaceuticals [1] - The STAR Market ETF (588090) has seen a surge in trading activity, with net inflows in 13 out of 16 trading days in July, accumulating 1.594 billion yuan, and its fund size approaching 5 billion yuan as of July 22 [1] Industry Distribution - The STAR 50 Index primarily covers industries such as new-generation information technology, biomedicine, and new materials, showcasing strong growth attributes [1] - Within the Shenwan secondary industry classification, the semiconductor sector holds a dominant weight of 61.04% in the STAR 50 Index [1] - The top five constituent stocks of the STAR 50 Index are leading semiconductor companies, including SMIC, Haiguang Information, Cambricon Technologies, Lattice Semiconductor, and Zhongwei Company, which are expected to continuously inject development momentum into the index [1] Fund Management - The STAR Market ETF (588090) is part of the first batch of index funds included in the personal pension product catalog, with its connected fund, Huatai-PB STAR 50 ETF Connect Y (022950), showing significant growth in fund shares, reaching 6.1 million shares, an increase of 5.6 million shares since the end of 2024 [2] - Huatai-PB Fund, as one of the first ETF managers in China, has over 18 years of ETF operation experience and manages a range of ETFs, including the leading Hu-Shen 300 ETF (510300) and other STAR Market ETFs, providing investors with diverse and convenient investment tools to share in the STAR Market's growth [2]

Group 1 - The Hong Kong stock market indices, particularly the Hang Seng Tech Index, experienced a significant rise, with the index increasing by over 2.5% in the afternoon session on July 23 [1] - The Hang Seng Tech Index ETF (513180) followed the index's upward trend, with notable gains in stocks such as NIO, Kingdee International, Baidu, Kuaishou, Tencent, and Meituan, with NIO rising over 10% [1] - The Chinese government has taken regulatory actions against food delivery platforms like Ele.me, Meituan, and JD.com, focusing on curbing aggressive promotional activities and ensuring compliance with regulations [1] Group 2 - According to Galaxy Securities, the absolute valuation of Hong Kong stocks is currently at a relatively low level, with the Hang Seng Tech Index ETF (513180) having a latest valuation (PETTM) of 21.14 times, which is below 82% of the time since its inception [2] - The report suggests that investors should focus on high-dividend stocks for stable returns amid global uncertainties, as well as sectors benefiting from favorable policies, such as stablecoin concepts, innovative pharmaceuticals, AI industry chain, and "anti-involution" industries [2] - Sectors that exceed expectations in mid-year performance are likely to see a rebound, indicating potential investment opportunities in the Hong Kong market [2]

Group 1 - The Hong Kong stock market has been active since early 2025, even leading global markets at one point, with an average daily trading volume increasing by approximately 80% compared to the same period last year [1] - Despite a weakening overall Chinese economic backdrop and ongoing external disturbances, a structural market rally has been observed, with sectors like AI, new consumption, and innovative pharmaceuticals experiencing multiple rounds of leadership [1] - The Hang Seng Technology Index's price-to-earnings ratio (PE TTM) remains at 21 times, indicating it is undervalued, with potential recovery in sectors such as e-commerce and local living services, supported by policy measures in the automotive sector [1] Group 2 - The Hang Seng Technology Index may see upward movement in the third quarter if earnings expectations are revised upward, combined with a recovery in market sentiment [1] - Investors are encouraged to consider the Hong Kong Technology ETF (513020), which tracks the Hong Kong Stock Connect Technology Index (931573), comprising up to 50 high-quality companies in the technology sector [1] - The index aims to reflect the overall performance of listed companies in the technology sector available through the Hong Kong Stock Connect, showcasing significant growth potential and market volatility characteristics [1]

Report Summary 1. Investment Rating of the Reported Industry There is no information provided regarding the investment rating of the reported industry in the given content. 2. Core Viewpoints of the Report The report analyzes the performance, scale changes, and portfolio configurations of active equity - biased funds in Q2 2025. It shows that in Q2, the North -交所 continued to lead the gains, the large - cap value style was dominant, and the average return of active equity - biased funds was 2.9%. The scale of equity - biased funds declined, the new fund issuance market improved, and the overall stock positions of equity - biased funds increased. Additionally, the funds continued to increase their positions in Hong Kong stocks, with changes in market - value styles and industry distributions [1][4]. 3. Summary According to the Table of Contents I. Active Equity - Biased Fund Market Review - **Performance Overview**: In Q2, the North -交所 led the gains, the large - cap value style was dominant, and the average return of active equity - biased funds was 2.9%. 70% of the funds had positive returns, and most single - quarter returns were between 0% and 5%. Funds heavily invested in innovative drugs, computing power, and the North -交所 performed outstandingly. The Hang Seng Index rose 4.1%, while the Hang Seng Tech Index declined 1.7%. Industries such as comprehensive finance and national defense and military industry led the gains, while the food and beverage industry had a large decline [4][9]. - **Scale Change**: At the end of Q2, the scale of equity - biased funds declined again, decreasing by 1% compared to the end of the previous quarter. The decline was mainly due to the redemption of fund shares. Funds with relatively large scale increases were mainly those heavily invested in military industry, innovative drugs, computing power, and new consumption. The scales of top - tier funds over 20 billion yuan all shrank to varying degrees [4][19]. - **New Fund Issuance Market**: The new fund issuance market improved, with a significant increase in the number and scale of newly issued funds in 2025Q2. A total of 72 active equity - biased funds were established, with a total scale of 37.419 billion yuan. The largest - scale newly established fund in Q2 was Dongfanghong Core Value, with a scale exceeding 1.9 billion yuan [29][35]. II. Position Analysis - **Position Analysis**: At the end of Q2, the overall stock positions of common stock, equity - biased hybrid, flexible allocation, and balanced hybrid funds were 90.10%, 88.49%, 85.77%, and 65.99% respectively, increasing by 0.75, 0.33, 0.87, and 3.21 percentage points compared to the end of the previous quarter [4][38]. - **AH Market Selection**: Active equity - biased funds that can invest in Hong Kong stocks continued to increase their positions in Hong Kong stocks in Q2, with the proportion of Hong Kong stocks in the stock investment market value increasing by about 1.6 percentage points. The Hong Kong stock positions have been increasing for 6 consecutive quarters [4][46]. - **Market - Value Style**: The proportion of the main board continued to decline slightly, while the proportions of the Science and Technology Innovation Board and the Growth Enterprise Market increased. The proportion of small - and medium - cap stocks below 5 billion yuan further increased by 0.76 percentage points [4][51]. - **Industry Distribution**: Active equity - biased funds increased their positions in TMT and financial real estate sectors and reduced their positions in consumption and mid - stream manufacturing sectors. Among the first - tier industries, the industries with the largest increase in heavy - position market value were communications, banking, and national defense and military industry, while the industries with the largest decrease were food and beverage, automobiles, and power equipment and new energy [4][56]. - **Heavy - Positioned Stocks**: At the end of Q2 2025, Tencent Holdings remained the largest heavy - positioned stock of active equity - biased funds, followed by CATL and Kweichow Moutai. Tencent Holdings was significantly reduced, while Inphi and Xinyisheng received the most increases in positions [4][64].

2、板块概念方面，雅江电站、创新药、券商、钢铁等板块领涨；海南、军工、电网设备、铜高速连接 等板块领跌； 3、两市共1968只个股上涨，55只个股涨停；2984只个股下跌，1只个股跌停；33只股票炸板，炸板率 37%。 1、市场早间震荡走强，沪指站上3600点关口。雅江电站概念股延续强势，中国电建、中国能建、铁建 重工等均3连板。券商等金融股拉升，国盛金控封板。创新药概念反复活跃，塞力医疗、昭衍新药等涨 停。下跌方面，军工板块调整，广联航空跌超10%。个股跌多涨少，沪深京三市超3200股飘绿，上午半 天成交1.16万亿。午间收盘沪指涨0.75%，深成指涨0.31%，创业板涨0.72%。 ...

Group 1 - The innovative drug sector experienced a significant surge, with Yinosh's stock rising over 15% during trading, driven by favorable policy changes and improvements in the company's fundamentals [1] - The National Healthcare Security Administration clarified the principle of "new drugs not included in centralized procurement," alleviating market concerns regarding the inclusion of innovative drugs in procurement, which is expected to enhance R&D investment enthusiasm among innovative drug companies [1][2] - Yinosh holds a 6.80% market share in the non-clinical safety evaluation sector, ranking third in the industry, with over 82% of its revenue from non-clinical research services for Class I innovative drugs [1] Group 2 - The non-clinical safety evaluation industry has high barriers to entry, with GLP certification being a core requirement, and only six CRO companies, including Yinosh, have obtained this certification from major regulatory bodies [2] - The innovative drug industry is experiencing a recovery in market conditions, with policies favoring innovative drugs and stable R&D investments from large pharmaceutical companies, providing growth momentum for CRO companies like Yinosh [2] - Yinosh has seen an 18.37% year-on-year increase in new orders for its core business of IND and NDA applications, indicating a positive trend in both domestic and international markets [1][2]

Core Viewpoint - The equity market continues to show a rebound trend from the "9.24" rally, while the fixed income market experiences fluctuations in a historically low-risk interest rate environment. Overall, various fund indices have yielded positive results in the first half of 2025 [1]. Equity Market - In the second half of 2025, the equity market is expected to face downward pressure but is supported by a stable economic fundamental. The introduction of further reforms in the Sci-Tech Innovation Board by the CSRC in June is anticipated to maintain market activity, although external complexities and domestic demand pressures may lead to a primarily fluctuating stock market with an upward central tendency [5]. - Key sectors to focus on include dividends, pharmaceuticals, military industry, and AI applications [5]. Fund Manager Insights - Fund Manager Yang Jiannan highlights the promising outlook for the pharmaceutical sector driven by innovative drugs, with domestic companies increasingly entering global markets through licensing agreements [6]. - Fund Manager Chen Bo emphasizes the rapid development of new productive forces, including AI and high-end manufacturing, and the rising penetration of spiritual consumption products [7]. - Fund Manager Lu Yang notes that large-cap indices have rebounded to median valuations, and investment strategies will focus on bottom-up stock selection based on industry competition and company performance [8]. Fixed Income Market - The fixed income market is characterized by a pragmatic approach, with limited expectations for significant interest rate cuts in the second half of the year. The central bank is expected to prioritize the stability of the banking system's liabilities and optimize policies based on macro-prudential principles [9]. - The market is likely to see a focus on short-term rates and credit products, with convertible bonds standing out due to their dual advantages in a resilient stock market [9]. Fund Manager Insights - Fund Manager Cai Weifeng reports a mixed strategy in the bond market, achieving moderate net value growth despite a challenging environment [10]. - Fund Manager Chen Fangfei observes that the bond market experienced fluctuations, with the central bank's actions providing some support, while maintaining a high duration strategy [12]. - Fund Manager Xu Jia notes that external risks have influenced bond market trends, with a focus on internal economic conditions as the market stabilizes [14].